A. Lahuerta

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

A. Guerrero-Zotano, R. Andrés, A. Llombart-Cussac, 2019, Scientific Reports.

Dynamic contrast-enhanced MRI versus 18F-misonidazol-PET/CT to predict pathologic response in bevacizumab-based neoadjuvant therapy in breast cancer.

J. García-Foncillas, S. Morales, I. Álvarez, 2012 .

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

R. Neuwirth, K. Galinsky, D. Slamon, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

L. de la Peña, E. Adrover, P. Zamora, 2019, Therapeutic advances in medical oncology.

A prospective study on tumour response assessments methods after neoadjuvant endocrine therapy in early oestrogen receptor positive breast cancer

A. Urruticoechea, K. Elorriaga, M. Otaño, 2023, medRxiv.

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

J. Herranz, J. Albanell, L. Gianni, 2022, Frontiers in Oncology.

A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma

J. Sludden, R. Plummer, P. Escribá, 2023, British Journal of Cancer.